Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
meta-analysis
prognosis
programmed cell death-ligand 1
triple-negative breast cancer
tumor-infiltrating lymphocytes
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
17 Sep 2020
17 Sep 2020
Historique:
received:
17
08
2020
revised:
07
09
2020
accepted:
13
09
2020
entrez:
22
9
2020
pubmed:
23
9
2020
medline:
23
9
2020
Statut:
epublish
Résumé
This meta-analysis aimed to evaluate the prognostic value of tumor-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1), their associations with the clinicopathological characteristics, and the association between their levels in patients with triple-negative breast cancer (TNBC). PubMed, EMBASE, Scopus, ProQuest, Web of Science, and Cochrane Library databases were searched to obtain the relevant papers. Seven studies with 1152 patients were included in this study. Like the level of TILs, there were no significant associations between PD-L1 expression and tumor size, tumor stage, lymph node metastasis, histological grade, and Ki67 (All
Identifiants
pubmed: 32957579
pii: diagnostics10090704
doi: 10.3390/diagnostics10090704
pmc: PMC7554852
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Onco Targets Ther. 2016 Aug 12;9:5023-39
pubmed: 27574444
J Breast Cancer. 2016 Sep;19(3):242-251
pubmed: 27721873
BMC Cancer. 2020 Mar 4;20(1):179
pubmed: 32131780
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Clin Cancer Res. 2013 Oct 15;19(20):5636-46
pubmed: 23873688
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Histopathology. 2016 Jul;69(1):25-34
pubmed: 26588661
Oncologist. 2011;16 Suppl 1:1-11
pubmed: 21278435
J Cutan Pathol. 2010 Apr;37 Suppl 1:48-53
pubmed: 20482675
Oncoimmunology. 2013 Jul 1;2(7):e24720
pubmed: 24073365
Int J Biol Sci. 2017 Sep 5;13(9):1172-1179
pubmed: 29104508
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Ann Intern Med. 2006 Mar 21;144(6):427-37
pubmed: 16549855
J Immunother Cancer. 2019 Feb 6;7(1):34
pubmed: 30728081
Clin Cancer Res. 2019 Sep 15;25(18):5717-5726
pubmed: 31227501
Breast Cancer Res Treat. 2014 Dec;148(3):467-76
pubmed: 25361613
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
Cancer Manag Res. 2018 Dec 10;10:6823-6833
pubmed: 30573992
Breast Cancer Res Treat. 2017 Jan;161(2):279-287
pubmed: 27888421
Oncotarget. 2017 May 9;8(19):31347-31354
pubmed: 28430626
Ther Adv Med Oncol. 2013 May;5(3):169-81
pubmed: 23634195
Stat Med. 1996 Mar 30;15(6):619-29
pubmed: 8731004
Cancer Sci. 2017 Jan;108(1):81-90
pubmed: 27801993
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Adv Radiat Oncol. 2018 Oct 23;3(4):520-526
pubmed: 30370351
Oncotarget. 2017 Feb 28;8(9):15584-15592
pubmed: 28107186
Cancer Biol Ther. 2018 May 4;19(5):373-380
pubmed: 29336717
Breast Cancer Res. 2018 Jun 22;20(1):62
pubmed: 29929548
Cancer Res Treat. 2019 Apr;51(2):649-663
pubmed: 30064200
Curr Opin Immunol. 2012 Apr;24(2):207-12
pubmed: 22236695
Front Immunol. 2020 May 15;11:940
pubmed: 32499786